Horn Howard sold $108K of RARE

Horn Howard (Chief Financial Officer) sold 7,066 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $15.27 ($0.11M total) on 2026-10-15.

Original reporting
SEC EDGAR · Horn Howard
Published Oct 19, 2026, 5:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 5:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RARE
Neutral
medium confidence
Mentioned
$RARE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RARENeutralLow
01

Why it matters

The CFO's sale reduces his ownership but remains a small fraction of total shares; market reaction is expected to be muted.

02

Market read

A modest insider sell with limited price impact; useful for monitoring but not a catalyst for major moves.

03

What to watch

Potential upcoming corporate actions or earnings that could change the interpretation of the sale.

Relevance 4/10Novelty 4/10Timing: post-filing today

Background

SEC Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$RARENeutralMedium confidence
Context

CFO Horn Howard sold 7,066 shares for $107,898, reducing his stake to 89,229 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

Form 4 filings are primary disclosures; the transaction size is modest, so impact is limited.

Market effects

Minimal effect on the biotech sector; insider sales are routine.

No broader regional impact.

Not globally relevant.

Counterpoint

The sale could be unrelated to company fundamentals and may be a routine liquidity move.

Key entities

  • Ultragenyx Pharmaceutical Inc.

    Biotech firm focused on rare disease therapeutics.

  • Horn Howard

    Chief Financial Officer of Ultragenyx.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy

Ultragenyx Pharmaceutical Inc (RARE) discontinued two gene therapy programs (GTX-102 and UX701) due to efficacy and trial advancement issues. The company is restructuring, cutting 20% of its workforce. The future of setrusumab for osteogenesis imperfecta is uncertain pending FDA discussions. R&D spending for 2027 is guided at less than $350 million, with a focus on commercial products. The company faces potential competition in the Sanfilippo syndrome type A market.

$RAREHighAI 8/10

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.